FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| OMB APPROVAL             |           |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  ORESHACK KURT  (Last) (First) (Middle)  C/O MARAVAI LIFESCIENCES HOLDINGS, INC. |  |    |            |        | 2. Issuer Name and Ticker or Trading Symbol MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]  3. Date of Earliest Transaction (Month/Day/Year) 04/29/2022 |  |  |       |  |      |   |   |          | tionship of F<br>all applicab<br>Director<br>Officer (g<br>below)  | 10% C other  |  | 10% Ov<br>Other (s<br>below)                  |  |  |
|---|--|----|------------|--------|---|--|--|-------|--|------|---|---|----------|--|--|--|---|--|--|
| 10770 WATERIDGE CIRCLE, SUITE 200  (Street) SAN DIEGO CA 92121  (City) (State) (Zip)                                      |  |    |            |        | 4. If A   | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |       |  |      |   |   | 6. Indiv | fividual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person |  |  |   |  |  |
|   |  | Та | ble I - No | n-Deri | ivativ  | e Se   | curitie  | s Acq | uired, l   | Disp | osed of,  | or l  | Benefi   | cially Ow  | /ned   |  |   |  |  |
| Date  |  |    |            |        | te<br>onth/Day/Year)  |  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)  |       |  |      | ties Acquired (A) or<br>I Of (D) (Instr. 3, 4 and |   |          | Securities<br>Beneficiall<br>Following   | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported<br>Transaction(s) |  | nership<br>: Direct (D)<br>lirect (I)<br>. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)        |  |
|   |  |    |            |        |   |  |  |       | Code   | v    | Amount  | Amount (  |          | Price  | (Instr. 3 an   |  |   |  | (instr. 4)   |
| Class A Common Stock 04/2   |  |    |            |        | /29/2022  |  |  |       | <b>A</b> <sup>(1)</sup>                                      |      | 394   |   | Α        | \$22.95  | 25,9   | ,931   |   | D  |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |    |            |        |   |  |  |       |  |      |   |   |          |  |  |  |   |  |  |
| 1. Title of<br>Derivative<br>Security (Instr. 3)  | tive Conversion Date Execution Date,   |    |            | ate,   | 4.<br>Transaction<br>Code (Instr.<br>8)   |  | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D) (Instr. 3, 4<br>and 5) |       | 6. Date Exercisable a<br>Expiration Date<br>(Month/Day/Year) |      | te  | e and 7. Title and Am<br>Securities Unde<br>Derivative Secu<br>(Instr. 3 and 4) |          | derlying<br>curity   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)                                      | 9. Numbe<br>derivative<br>Securities<br>Beneficia<br>Owned<br>Following<br>Reported<br>Transacti | e<br>s<br>lly                                 | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |    |            |        | Code  | v  | (A)  | (D)   | Date<br>Exercisa   |      | Expiration<br>Date                                | Title   | •        | Amount<br>or<br>Number<br>of Shares  |  | (Instr. 4)   | , ,   |  |  |

## **Explanation of Responses:**

1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 394 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

## Remarks:

/s/ Kurt Oreshack

04/29/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.